Suspended
Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma
What is being tested
Data Collection
Who is being recruted
Neoplasm Metastasis+5
+ Neoplasms
+ Neoplasms by Histologic Type
Over 18 Years
+21 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Study Start: August 2003
Summary
Principal SponsorEnzon Pharmaceuticals, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: August 1, 2003
Actual date on which the first participant was enrolled.The purpose of this study is to evaluate the safety and efficacy of Pegamotecan (Peg-Camptothecin) in patients with Advanced or Metastatic Soft Tissue sarcoma.
Official TitleEfficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma
Principal SponsorEnzon Pharmaceuticals, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Neoplasm MetastasisNeoplasmsNeoplasms by Histologic TypeNeoplastic ProcessesPathologic ProcessesSarcomaPathological Conditions, Signs and SymptomsNeoplasms, Connective and Soft Tissue
Criteria
9 inclusion criteria required to participate
Histologically or cytologically confirmed diagnosis of soft tissue sarcoma with measurable disease.
Target tumors outside prior radiation field(s).
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Adequate hematologic profile, as determined by hemoglobin, platelet, and neutrophil count.
Show More Criteria
12 exclusion criteria prevent from participating
Subject has a diagnosis of gastrointestinal stromal tumors.
Concurrent serious medical illness unrelated to tumor within the past 6 months.
Known chronic infectious disease, such as AIDS or hepatitis.
Positive screening pregnancy test or is breast-feeding.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 4 locations
Suspended
Suspended
Pennsylvania Oncology Hematology Association
Philadelphia, United StatesSuspended
University of Pittsburgh Cancer Institute
Pittsburgh, United StatesSuspended
Institute for Drug Development Cancer Therapy and Research Center
San Antonio, United StatesSuspended4 Study Centers